European registry on helicobacter pylori management (hp-eureg): First-line therapy in Israel

Keyphrases

• Adverse Events 20%
• Antibiotic Sensitivity 20%
• Best Practice Guidelines 20%
• Clarithromycin 60%
• Clinical Data 20%
• Concomitant Therapy 20%
• Current Treatment 20%
• Data Diagnostics 20%
• Days of Treatment 20%
• Diagnostic Test 20%
• Drug Regimen 20%
• Eradication Rate 20%
• European Registries 100%
• Event Outcomes 20%
• Evidence-based Practice 20%
• First-line Therapy 100%
• Helicobacter Pylori (H. pylori) 100%
• Helicobacter Pylori Infection 20%
• Helicobacter Pylori Treatment 20%
• Hp-EuReg 100%
• International Guidelines 20%
• Israel 100%
• Modified Intention-to-treat 20%
• Multicenter Cohort Study 20%
• Overall Effectiveness 20%
• Per-protocol Analysis 20%
• Proton Pump Inhibitors 60%
• Sequential Therapy 20%
• Tertiary Care Hospital 20%
• To Determine the Effectiveness 20%
• Treatment Compliance 20%
• Treatment Efficacy 20%
• Treatment Outcome 20%
• Treatment Protocol 20%
• Triple Therapy 60%

Medicine and Dentistry

• Adverse Event 16%
• Antibiotic Resistance 16%
• Clarithromycin 50%
• Combination Therapy 16%
• Diagnostic Test 16%
• Drug Megadose 33%
• Helicobacter Infection 16%
• Helicobacter Pylori 100%
• Intention-to-Treat Analysis 16%
• Low Drug Dose 16%
• Patient Compliance 16%
• Patient Referral 16%
• Proton-Pump Inhibitor 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 16%
• Antibiotic Resistance 16%
• Clarithromycin 50%
• Combination Therapy 16%
• Helicobacter Infection 16%
• Helicobacter Pylori 100%
• Proton Pump Inhibitor 50%